Sort
39,280 grants matching “leukemia”
Development of gene therapy for wiskott-aldrich syndrome (WAS)
$365,043Arthur W. Nienhuis · St. Jude Children'S Research Hospital · P01 · FY2014 · HL
Evaluation of self-inactivating lentiviral vectors for treating SCID-X1 patients
$365,043Brian P Sorrentino · St. Jude Children'S Research Hospital · P01 · FY2014 · HL
Chromosomal alterations in basic mechanisms of radiation injury
$365,033Susan M. Bailey · Colorado State University · R01 · FY2010 · AI
Identification of stromal responses during castration-induced thymic regrowth.
$365,007Howard T. Petrie · Scripps Research Institute, The · R01 · FY2013 · AG
FUNCTIONS OF E2A IN B LYMPHOCYTE DEVELOPMENT
$365,005Duke University · R01 · FY2002 · CA
Hematopoietic stem cell gene therapy for sickle cell disease
$365,003Derek A Persons · St. Jude Children'S Research Hospital · U54 · FY2011 · HL
Understanding and predicting relapse in acute myeloid leukemia
$364,998Jerald P Radich · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA
Lineage-specific reprogramming to blood with a transcription factor cocktail
$364,979Michael Kyba · University Of Minnesota · RC1 · FY2010 · HL
Molecular Biology of Polycythemia
$364,967Josef T Prchal · University Of Utah · R01 · FY2006 · HL
The Role of LMO2 in the Pathogenesis of T-cell Leukemia
$364,962Utpal P Dave · Indiana University Indianapolis · R01 · FY2018 · CA
The Role of LMO2 in the Pathogenesis of T-cell Leukemia
$364,962Utpal P Dave · Indiana University Indianapolis · R01 · FY2017 · CA
Role of the pre-T cell receptor in lineage commitment
$364,947Harald Von Boehmer · Dana-Farber Cancer Inst · R01 · FY2008 · AI
Role of the pre-T cell receptor in lineage commitment
$364,947Harald Von Boehmer · Dana-Farber Cancer Inst · R01 · FY2009 · AI
MECHANISMS OF TRANSCRIPTIONAL REPRESSION IN DROSOPHILA
$364,938Fred Hutchinson Cancer Research Center · R01 · FY2002 · GM
Increased Sensitivity of Minimal Residual Disease Monitoring using Peripheral Blood in Pediatric Patients with Acute Lymphoblastic Leukemia
$364,903Steven A. Soper · University Of Kansas Lawrence · R33 · FY2020 · CA
Endocrine disrupter modulation of SXR in development and lymphomagenesis
$364,901Bruce Blumberg · University Of California-Irvine · R01 · FY2017 · ES
Natural Product Leads for Drug Development
$364,846Kathlyn A Parker · State University New York Stony Brook · R01 · FY2007 · GM
Molecular Mechanism of Leukemogenesis Involving AML1-ETO
$364,846Dong-Er Zhang · Scripps Research Institute, The · R01 · FY2007 · CA
The role of the nucleoporin Nup98 in gene regulation
$364,800Martin W Hetzer · Salk Institute For Biological Studies · R01 · FY2015 · GM
The role of the nucleoporin Nup98 in gene regulation
$364,800Martin W Hetzer · Salk Institute For Biological Studies · R01 · FY2012 · GM
The role of the nucleoporin Nup98 in gene regulation
$364,800Martin W Hetzer · Salk Institute For Biological Studies · R01 · FY2014 · GM
Validating a novel biomarker of clinical progression and survival in CLL
$364,740Randall S Davis · University Of Alabama At Birmingham · R33 · FY2013 · CA
Chaetocin as a Potential Therapy for Multiple Myeloma
$364,721Keith C Bible · Mayo Clinic Rochester · R01 · FY2009 · CA
Antileukemic effort of NK cells in HCT for pediatric AML
$364,712Wing Leung · St. Jude Children'S Research Hospital · R01 · FY2008 · CA
MODULATION OF IFN ACTION VIA NOVEL REGULATORY FACTORS
$364,709University Of Maryland Baltimore · R01 · FY2002 · CA